Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 15, 2023

SELL
$285.76 - $321.48 $1,143 - $1,285
-4 Reduced 2.41%
162 $46.8 Million
Q3 2022

Nov 08, 2022

BUY
$273.83 - $305.53 $547 - $611
2 Added 1.22%
166 $48.1 Million
Q2 2022

Aug 16, 2022

BUY
$234.96 - $292.55 $38,533 - $47,978
164 New
164 $46.2 Million
Q1 2022

May 11, 2022

SELL
$221.42 - $260.97 $1,107 - $1,304
-5 Closed
0 $0
Q2 2021

Jul 30, 2021

BUY
$187.49 - $221.1 $937 - $1,105
5 New
5 $1,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Atlas Capital Advisors LLC Portfolio

Follow Atlas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Capital Advisors LLC with notifications on news.